Blog - Page 3 of 9 - COPE

COPE supported centers are pleased to provide a blog for patients and family members of patients that provides more information on ketamine treatments and mental illness.


Depression, Gratitude, and Mental Health

One of the common misunderstandings about depression is that it's a choice. Depression is more than just feeling sad and it can be hard to be grateful even during the holiday season.

Relative Efficacy Ketamine : Does the Formulation and Delivery Matter with Respect to Efficacy, Tolerability and Safety?

In March of 2019, the US FDA approved intranasal esketamine for treatment-resistant depression (TRD). Conceptually, this is an extraordinary event from the point of view of drug development in psychiatry insofar as this is the first time the FDA has approved an antidepressant medicine that was developed on the basis of an a priori diseases model (i.e. glutamatergic dysregulation relevant to the pathogenesis of mood disorders).

Can We Predict Who will Respond to Ketamine/Esketamine in TRD?

The heterogeneity of treatment response in MDD has provided a compelling rationale for identifying predictors of response/tolerability (and non-response/intolerability) amongst individuals assigned to a given treatment. The need to identify predictors of response is even greater when the treatment options being considered are more costly, require more resources for administration (e.g. specialized clinics), and/or may be associated with greater safety/tolerability concerns.